The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
Retrospective evaluation of indications for therapeutic plasmapheresis procedures applied in our center
Aims: Therapeutic plasma exchange (TPE) is a process in which pathological substances (autoantibodies, alloantibodies, immune complexes, lipoproteins, cryoglobulins, etc.) in the patient's plasma are removed from the body along with the patient's plasma and replaced with replacement fluid (allogeneic donor plasma, colloid, crystalloid). It is applied as a complementary treatment method in many diseases that can cause high morbidity and mortality, either in the primary treatment of the disease (main treatment) or as an adjunctive treatment in the main treatment of the disease. Today, TPE is increasingly used in various clinics (toxicology, endocrinology, etc.) for different diseases/causes, especially in hematological, neurological, and nephrological diseases.
Methods: Adult patients who underwent therapeutic plasma exchange in our therapeutic apheresis center between May 2017 and May 2019 were included in the study, and the data were obtained by retrospectively reviewing patient records in the therapeutic apheresis center and our hospital's automation system.
Results: In the two-year period, a total of 1957 TPE procedures were performed on 441 patients. It was determined that 255 of the patients undergoing TPE procedures (57.8%) had indications related to liver diseases (acute liver failure, acute exacerbation of chronic liver failure, and rejection after liver transplantation), while 186 (42.2%) had indications related to non-liver diseases. Among the 186 patients undergoing TPE for non-liver diseases, it was found that 69 (37.1%) were for hematological, 38 (20.4%) for neurological, 32 (17.2%) for renal, and 47 (25.3%) for other diseases.
Conclusion: Due to the large number of liver transplants performed in our Liver Transplant Institute, the majority of TPE indications at our hospital are related to liver diseases. However, the evaluation of TPE indications excluding liver diseases revealed that the indications and frequencies of patients undergoing TPE were consistent with the overall results reported in studies from both our country and abroad.

1. Winters JL. Plasma exchange: concepts, mechanisms, and an overview ofthe American Society for Apheresis guidelines. Hematol Am Soc HematolEduc Program. 2012;2012(1):7-12.
2. Williams ME, Balogun RA. Principles of separation: indicationsand therapeutic targets for plasma exchange. Clin J Am Soc Nephrol.2014;9(1):181-190.
3. Doğu MH, Kabukcu Hacıoğlu S. Alternative treatment optiontherapeutic apheresis diagnosis and clinical approach 5 year experience.Acta Oncologica Turcica. 2018;50(3):218-223.
4. Sergent SR, Ashurst JV. Plasmapheresis. In:StatPearls. Treasure Island(FL): StatPearls Publishing; 2023.
5. Polat M, Ceylan BG, Alanoglu G, Eroglu F, Sipahi T. Süleyman DemirelÜniversitesi Hastanesi yogun bakım ünitesi plazmaferez uygulamaları.SDÜ Tıp Fak Derg. 2009;16(4):1-4.
6. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasmaexchange: a prospective study of 1,727 procedures. J Clin Apher.2007;22(5):270-276.
7. Ersan S, Ersan GA. Two-year analysis of therapeutic apheresis practicesin a tertiary center: are we chasing the new indications? Hippokratia.2018;22(4):167-172.
8. Arslan Ö, Arat M, Tek I, Ayyildiz E, Ilhan O. Therapeutic plasmaexchange in a single center: Ibni Sina experience. Transfus ApheresSci. 2004;30(3):181-184.
9. Ataca P, Marasuna OA, Ayyildiz E, Bay M, Ilhan O. Therapeuticplasmapheresis in geriatric patients: favorable results. Transfus ApheresSci. 2014;51(3):64-67.
10. Korkmaz S, Solmaz Medeni S, Demirkan F, et al. The Turkish experiencewith therapeutic plasma exchange: a national survey. Transfus ApheresSci. 2019;58(3):287-292.
11. Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasmaexchange in patients with acute liver failure: an open randomisedcontrolled trial. J Hepatol. 2016;64(1):69-78.
12. Clemmesen JO, Kondrup J, Nielsen LB, Larsen FS, Ott P. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patientswith acute liver failure.Am J Gastroenterol. 2001;96(4):1217-1223.
13. Li M, Wang Z, Wang Y, et al. Part of plasmapheresis with plasmafiltration adsorption combined with continuous hemodiafiltrationin the treatment of severe acute liver failure. Exp Ther Med.2016;12(4):2582-2584.
14. Jin D, Kang K, Yan BZ, et al. Combined age with mean decrease rates oftotal bilirubin and MELD score as a novel and simple clinical predictoron 90-day transplant-free mortality in adult patients with acute liverfailure undergoing plasma exchange: a single-center retrospectivestudy.Can J Gastroenterol Hepatol. 2023;2023:6115499.
15. Stahl K, Busch M, Fuge J, et al. Therapeutic plasma exchange in acute onchronic liver failure. J Clin Apher. 2020;35(4):316-327.
16. Tan EXX, Wang MX, Pang J, Lee GH. Plasma exchange in patients withacute and acute-on-chronic liver failure: a systematic review. World JGastroenterol. 2020;26(8):219-245.
Volume 2, Issue 2, 2024
Page : 28-32